echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > The PLUS KRAS G12C inhibitor completes the first patient administration of the STK11 co-mutant IIa trial

    The PLUS KRAS G12C inhibitor completes the first patient administration of the STK11 co-mutant IIa trial

    • Last Update: 2022-09-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Jiacosi Pharmaceuticals (1167.


    JAB-21822 is a KRAS G12C inhibitor independently developed by JIAX USING ALLOPHO INHIBITOR technology, which is used for the first-line treatment


    About 40,000 new tumor patients with KRAS G12C mutations are added to China every year, and STK11 is a parallel biomarker


    Dr.


    JIACOS's KRAS G12C inhibitor JAB-21822 is the potential best of its kind for KRAS G12C inhibitors


    At present, JAB-21822 is conducting simultaneous single-drug and combination clinical studies


    Jiacosi Pharmaceuticals (1167.


    JAB-21822 is a KRAS G12C inhibitor independently developed by JIAX USING ALLOPHO INHIBITOR technology, which is used for the first-line treatment


    About 40,000 new tumor patients with KRAS G12C mutations are added to China every year, and STK11 is a parallel biomarker


    Dr.


    JIACOS's KRAS G12C inhibitor JAB-21822 is the potential best of its kind for KRAS G12C inhibitors


    At present, JAB-21822 is conducting simultaneous single-drug and combination clinical studies


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.